Q2 2020 Zoetis Inc Earnings Call
Hi, how are you.
[music].
That's it again.
I mean, I don't know [laughter] finding though.
No.
Well good luck in quarter, two bobbing 20 financial results conference call with <unk> capital level I.
During the call today, let's be Frank Vice President Investor Relations and limited.
Anything taking materials in additional financial table are currently posted on the Investor Relations section is already dotcom three patients lives can be mainly by you you weren't and will not be followed it automatically. In addition, a replay of this call <unk> available approximately two hours after the conclusion of this.
Called me, a dilution or on the Investor Relations section, you'll let us dot com at this time all participants have been placed anything only known and this will be open for questions. Following the presentation.
He would like to ask the question at that time. Please press star one on your type strong phone if at any point. Your question has been answered he may lose yourself in the queue I'd like in the pound T. Any interesting tiny I say you limit yourself to one question in queue up again with any follow up your line moving it isn't going up and when you complete.
Your question.
Taking your question. Please pick up your hands that to a lot more sound quality last we have easy requiring operator assistance. Please press star zero now my pleasure carrying a whole over to Steve Frank Steve You may begin.
Good morning, everyone.
Second quarter 2020 earnings call I'm joined today by [laughter], Our Chief Executive Officer, Glenn David Our Chief Financial Officer.
Again, I'll remind you that flags presented on this call are available on the Investor Relations section of our website.
Remarks today will include forward looking statements and that actual results could differ materially from those production.
List and description of certain factors that could cause results to differ I refer you to.
Forward looking statement in today's press release, and Iraqi filings, including but not limited to our annual report on form 10-K, and our report on form 10-Q.
My remarks today will also include references to certain financial measures, which were not prepared in accordance with generally accepted accounting principle or U.S. GAAP. A reconciliation of these non-GAAP financial measures to the most directly comparable us GAAP measures is included in the financial table that accompany our earnings press release and as a company 8-K.
Filing dated today August six 2020, we also state operational results, which exclude the impact of foreign exchange.
With that I will turn the call over to Kristen.
Thank you Steve Good morning, everyone I Hope you and your loved ones remain safe and healthy as a cobot 19 pandemic continue to affect all of our professional and personal lives.
The call today, he will provide additional context around the impact of Coburn 19 is having on our business.
All right the quarterly financial results.
You on our outlook and leave plenty of time to address your question.
In the second quarter, we delivered better than expected results given uncertainty around the Kogan 19 pandemic I want to thank all of our the widest colleagues were shown amazing resiliency customer focus and perseverance throughout the year in response to these challenging time.
In terms of numbers, our revenue grew 4% operationally with the U.S. segment up 6% and international up 3%.
Our companion animal products continued to drive our business performance with 13% operational growth by livestock products declined 5%.
Our adjusted net income increased 4% operationally in the second quarter.
We have built very strong companion animal portfolio over the last several years based on our internal innovation.
These products have helped offset some of the deeper market challenges in the livestock market today.
Our recently launched Parasiticides compared to trio per works, well and revolution spot as well other key dermatology portfolio and outgrow inside a point provide a solid foundation that has continued to perform well this year.
We continue to be very pleased with the performance of our new Triple combination parasiticide for dogs sincerity trio as well the strength of the overall compared to franchise.
Glenn will share more details in his remarks.
Our continued focus on meaningful innovation and the diversity of our portfolio across Pcs products and geographies remain core advantages for do added during times of economic uncertainty and we've also seen the essential nature of animal health, playing an important role in the resiliency of our business and are in.
Industry at this time.
In terms of Cobot 19, our veterinary and producer customers are under increased pressure to deliver critical animal care and maintain a reliable global food supply and we are fortunate to be able to support them in this mission.
We continue to put the safety of our colleagues and customers first during this pandemic and we're very pleased with our team's ability to maintain productivity, even with safety and social distancing adjustments at our facilities as well as the ongoing you have remote work arrangements for the majority of our colleagues.
Our field force has returned to meeting with customers in many geographies based on local guidance and practices.
We monitor it adaptive plans on a daily basis based on local feedback and adjustments in markets that may be experiencing increased cobot 19 cases.
Our teams are excited to be back out with our customer, but we're also preserving the lessons we've learned from effective online interaction webinars and ecommerce to evolve our sales and support.
In terms of supply chain. The weather has maintained a reliable inventory of critical medicines vaccines and diagnostics to our customers and distributors and more than 100 markets around the world and our research development programs remain on track in terms of filings clinical trials.
Interactions with regulatory agencies.
We remain confident in the progress of regulatory reviews of our monoclonal antibody candidate for pain in cats and dogs.
Our submissions are proceeding as expected.
Your continues to be uncharted territory, you recover 19, and the related trends affecting our customer however, the underlying demand for healthy Pat and a reliable source of protein remains fundamental to the global economy.
In the second quarter, we benefited from the veterinary clinics in the U.S. recovering much more quickly from the cobot 19 impact than we anticipated.
Veterinary practices in the U.S. adapted quickly the current site visits and mobile clinics to deliver critical care and maintain relationships with their customers.
We also saw an acceleration of companion animal products sales through E Commerce channel as a result, the lockdowns in many states veterinarians and pet owners are adapting more quickly to these online auction as a way to fill prescriptions for parasiticides and other medicines.
We also know people are spending more time at home with their path. They may be observing conditions, such as you know or pain, which had previously gone unnoticed and so we're actually seeing an increase in spend per visit us clinics.
Meanwhile, outside the U.S. companion animal Veterinary clinic performance has been inline with expectations. Despite wide market by market variations based on local dynamics.
For the awareness, we expect our overall revenue growth for the remainder of the year to be driven largely by companion animal products, especially our parasiticide and key dermatology portfolio, we plan to continue investing and direct to consumer advertising and digital marketing to support these products.
Livestock is a very different picture and remains very challenged by the pandemic, especially in the us.
Producers are adjusting to new market demands and distribution needs from foodservice and restaurant channels to more grocery and retail channel, while also managing ongoing labor safety and trade issues.
As expected unit livestock in the second quarter saw significant downturn as we expect that to remain a challenge for the rest of the year.
The pace of return to more foodservice and restaurant demand along with increased export opportunities will be the most significant factor in the recovery of livestock producers in the U.S.
Internationally livestock grew and performed inline with expectations across a diverse set of markets.
We saw very positive results in places like China, where their further along in the cobot 19 recovery, but we will be sensitive to see how Latin America and markets like Brazil perform in the remainder of the year due to coated.
As we look ahead, we remain focused on advancing our five key priorities to ensure our long term success.
Driving innovative growth.
Enhancing customer experience.
Leading in digital and data analytics.
Cultivating a high performing organization and championing a healthier more sustainable future.
We continue to made important investments in product innovations across the continuum of care from prediction in prevention detection and treatment of disease.
With the approval of our Vanguard B oral for dogs in Brazil.
<unk> terrible PCB, MH and fresh air Gold PCV medicine him for vaccines for pigs in Australia.
We also continued to strengthen our diagnostic and digital capabilities building on recent acquisitions and pointed care and reference lab along with additional investments.
We plan to launch a new diagnostic platform for pet care and the third quarter called that scanned images. We are very excited about the potential for this disruptive innovation, which will be the first system to bring clinical technology right to the point of care.
This new multipurpose platform uses a combination of image recognition technology algorithm and cloud based artificial intelligence to deliver rapid testing results to the clinic.
It is first indication will be protesting fecal samples for parasites, making it quick and easy to test and treat pets and the same visit.
Have more to say in the coming week as we prepare for global lunch.
We also view diagnostic is playing it important role and the continuum of care for fish and the second quarter, We acquired Fischbeck group to add more diagnostic tool to our agriculture portfolio, including environmental testing, which is critical to fish farming.
Finally, after lettuce or T priority around high performing team is tied to creating a culture, where all colleagues feel valued and included in is reflected in our commitment to promoting inclusion diversity and equity across our organization.
Our leadership in board are dedicated to being a force for positive change across the globe to drive greater equity and inclusion and we are dedicated financial and people resources to do so.
As part of it plan, we've made commitments to public our diversity statistics and to increase our representation of black colleagues and people of color overall in the U S.
As the World leader, an animal health, we are committed to demonstrating our leadership on this important business and social issue.
Now, let me hand, after Glen who will speak more about our second quarter results and updated guidance for the full year Glen.
Thank you Crystal and good morning, and hope everyone's suits healthy and adapting to what is certainly an unprecedented time for all of us.
So they will provide additional commentary on a cue to financial results.
Provided an update on a liquidity position and redo are improved full year 2020 guidance.
Beginning with the second quarter results, we generated revenue of 1.5 billion.
Which was flood on Ah reported basis, and 4% growth operationally.
Adjusted net income a 427 million.
Decreased 2% on Ah reported basis and increased 4% operation.
Foreign exchange in the quarter at an unfavorable impact a 4% on revenue.
This was driven primarily by the U S dollar strengthening against the Brazilian Rio Australia.
Mexican peso in Europe.
Operational revenue growth, a 4% was driven by 2% price and 2% bone.
Volume growth, 2% includes 3% from new products, 3% from <unk> dermatology products, 1% from acquisitions and a decline it 5% and the other inline products.
Component animal products led the way in terms of species growth growing 13% operationally, while livestock declined 5% operation.
Companion performance was driven bioterror set aside portfolio, which includes sales of some parakeets real in the U S, Canada and certain European markets and our key dermatology products Apropos insider point.
Revenue from the acquisition of Plotner performance M as nutritional products acquired and the second half of 2019 drove the growth and <unk>.
Lifestyle declines in the quarter were driven by challenges to a U S lifestyle portfolio.
Supply chain disruptions caused by reduced animal processing capacity and shifts and consumer demand from restaurant and foodservice to grocery stores affected our customers purchasing decisions.
This decline was partially offset by strong performance internationally with growth and swine fish and poetry.
New products contributed 3% to overall growth in the quarter driven by some power to trio for 12 Revolution plus.
Floats parasiticide for salmon and chili.
We remain excited by the launch a some parakeet trio and Ah reaffirming the range of $100 million to $125 million for full year incremental revenue.
While clinic penetration is occurring at a more moderate peace as a result of the cold at 19 pandemic.
Prescriptions and those clinics that have adopted trio have been more robust and cannibalization of some perrigo has been less than we anticipated.
Global sales of a key dermatology portfolio, where $224 million in the quarter growing 24% operationally and contributing 3% overall revenue growth.
Recent acquisitions contributed 1% growth this quarter, which includes apartment performance and a reference lab expansion strategy.
Now, let's discuss the revenue growth by segment for the quarter.
<unk> revenue grew 6% with companion animal products growing 19% and lifestyle products declutter declining by 18%.
Companion animal growth in the quarter were driven by itself does have some power franchise R. T dermatology products and the impact of recent acquisitions.
U S key dermatology sales were 160 million for the quarter growing 26%.
The continue strength of this portfolio was driven by expanded usage of both side of point and apical benefiting from a direct to consumer campaign uptake in E commerce channels and pet owners spending more time with their pets as a result of program 19.
Some parakeets real perform well in the U S with sales of 36 million.
Despite challenging market conditions in Q too.
We're observing several positive trends included rapid I'll take an clinic that have adopted trio <unk>.
Small unexpected cannibalization of some perrigo.
Sales coming from new patients through the category and taking sure from current oral plan to competitors.
Diagnostic sales increased 18% in the quarter, largely driven by a reference lab acquisitions.
In addition, previous instrument placements created a solid foundation for consumables growth and the second quarter.
U S livestock declined 18% mcwhorter, driven by lower sales across all species.
And the second quarter, we face challenges with significant declines in feedlot placements reduced demand from the foodservice industry and the effects that had throughout the food supply chain and our customers. In addition to increased competition.
To summarize U S performance was strong and a difficult market environment and the diversity of our portfolio again proved beneficial is growth and companion animals offset the challenges faced and the U S by our lifestyle portfolio.
Our international segment had operational revenue growth of 3% and the second quarter.
With more balanced performance across our companion animal and livestock portfolios.
Companion animal operational revenue growth was 2% and livestock operational growth with 4%.
Increased sales and competitor animal products will the result of growth and our key dermatology portfolio and are some power to franchise, including launch a some power trio in Canada.
While European markets, where impacted significantly by Cove in 19, the decline was offset by significant growth and other markets, including Japan and China.
Diagnostics at a difficult quarter as Widescale clinic closures, resulting from <unk> 19 limited the ability to place instruments and negatively impacted consumable usage.
International livestock growth in the quarter was driven by swine fish and poultry.
Swine grew double digits in the quarter, primarily driven by China, which grew 25% is key account's continued to expand their herds and production shifts from small farms to larger scale operations.
Our fish portfolio delivered another strong quarter.
We saw favorable conditions and chili in Norway that resulted in vaccinations being accelerated into Q too.
In addition, we continue to see in uptake of the Alpha flux Parasiticide and chili.
Overall, our international segment was again, a positive contributor to revenue growth with performance and swine companion animals fish and poultry more than offsetting decline in cattle, resulting from the code with 19 pandemic.
Now moving onto the rest of the piano.
Adjusted gross margin of 71, 1% increase slightly on Ah reported basis compared to the prior year due to price favorable manufacturing costs and product mix, which were partially offset by foreign exchange recent acquisitions and higher inventory charges.
Oh, just the the operating expenses were flat operationally.
The incremental advertising and promotion expenses related to some power trio recent acquisitions and R&D increases will largely offset by reduction to teenie and compensated related costs as a result of coven 19.
The adjusted effective tax rate for the quarter was 22, 3%.
The increase versus prior year is driven by the jurisdictional mix of earnings and the impact of discreet tax benefits recorded and Q2 2019.
Adjusted net income for the quarter grew 4% operationally, primarily driven by revenue growth.
And adjusted diluted EPS through 6% operation.
Next I'd like to cover a liquidity position and a capital allocation priorities.
We ended the second quarter, what approximately three $4 billion in cash in cash equivalents, including the proceeds from Ah 125 billion long term that issuance in may of which $500 million is earmarked repayment of our November 2020 matured.
We have access to a $1 billion revolving credit facility and a coincide and commercial paper program, both of which remain on drawing.
Given a strong cash flow and balance sheet will remain committed to our capital allocation priorities for internal investment M&A and returning extra cash shareholders.
Consistent with what I mentioned last quarter, we still anticipate elevated capital expenditures this year, so support investments in manufacturing.
Information technology to support a recent acquisitions and capabilities and digital and data analytics.
With regard to returning excess cash to shareholders will remain committed to our 2020 dividend, which represents of 22% increase over 2019.
And Q1, we repurchased $250 million into the lettuce shares before suspending the program and the second quarter in order to conserve cash.
We have approximately one 4 billion remaining under a multiyear share repurchase program.
Now moving onto our updated guidance assumptions for 2020.
Our past performance has always given this confidence that the central nature of our business diverse portfolio and the innovation, we consistently bring to our customers with position as well during difficult market conditions.
After assessing recent trends in our performance and the second quarter, we're further refining and raising our full year 2020 guidance.
We expect recent positive companion animal trends in the U S will continue although vet clinic revenue may moderate somewhat is pent up demand works its way through the system.
Alternatively, we believe social distancing measures are negatively impacting foodservice recovery and will continue to present challenges to our lifestyle business in the U S.
The more recent resurgence of Kobe, 19 cases and parts of the U S.
And expanding rates of infection in international markets continues to create uncertainty around the duration scope and economic impact of the pandemic.
Please note that are guidance reflects foreign exchange rates as of mid July and given a global footprint movement Foreign exchange has had an impact on revenue and adjusted net income since we issued a prior guidance and make.
Ah current guidance includes favorable foreign exchange revenue of approximately $50 million and approximately $10 million. It adjusted net income versus made guidance.
For revenue, we're raising <unk> or guidance range with projected revenue now between six three and six 475 billion.
And operational revenue growth of between three and 6% for the full year versus the negative too so positive 3%, we haven't made guidance.
Adjustment income is now expected to be in the range of between 1685, and 176 5 billion <unk>.
Representing operational growth a positive one to positive 5% compared to our prior guidance of negative nine to negative 2%.
Adjusted diluted EPS is now expected to be in the range of $3 52 to $3 68.
And reported diluted EPS to be in the range of $3 and 14 to $3 32.
And closing while the Kobe 19 pandemic is certainly presented a set of challenges we have not seen in the past where extremely proud of our colleagues and the commitment they have shown toward our customers our company and animal health care.
During this time, we have demonstrated the diversity and durability of our portfolio the resiliency of our industry and we have confidence in our ability to continue to execute on strategy. During these on certain time.
I'll have things over to the operator to open the line for your questions operator law.
Her name Apple Fine as you would like to ask the question as a reminder, that installed and one.
So I'll take our first question from <unk>.
Please go ahead.
Thanks, guys I guess I'll try to just load everything abroad.
Mortgage where it an all time pie limits of a global pad debit so congrats but.
That was likely aided by mix. It seems like that mixed may remain as you mentioned intact a favorable for the next couple of quarters. So as we think about margins into the back part of the year is there any nicole out overall.
And what about the cadence of <unk> versus four Q Christian for you just to shipped over there maybe if you can just talk to what you're seeing for a competitive response on trio and just a clarification the new platform for diagnostics with a new offering is that even partly new bet skin and a larger that displaces the old one or is it a.
Different units specific pathology, a lot there, but thanks for your dog.
Okay.
The address the first part of your question with our operating margins and mix. So as you say, we have very favorable gross margin and this quarter as well as the first half of the year as we look into the second half of the year, we do expect to be there'll be some deterioration and gross margin and that does come from product mixed right to the separation that we've seen in performance.
And the quarter livestock declined 5% operationally companion animal grow through 13%, we expect that to narrow and the second half of the year the differential and performance between companion animal lifestyle. So that will negatively impact mix. The other component is that we generally have a larger portion of livestock sales and the second half of the year than we do have an.
The first half of the year. The other components to consider is opex right as we move into the second half of the year and I'll field returns more and more to visiting clinics <unk> expenses, which has been very favorable, particularly in Q2 will rise as we go into Q3 Q for in terms of the dynamics between Q3 Q for don't.
Really see any big differential in terms of the dynamics between Q3 Q for.
Okay, Hey, John with regards to your question Uncompetitive response to trio, it's been a response that we largely expected. Obviously this is an innovative product.
They were very where it was coming there obviously running promotions you probably sauce in stock and as we probably saw it moved from Q1 kick you too, but we're really not seeing anything that we weren't expecting overall and your address your other question with regards to images. It's a completely separate product. It is actually a scanner and a microscope.
Then upload for the cloud for analysis. So it it's completely separate Vanity pet scan and it Ah platform in the first product we mentioned will be around sequel funny does not a replacement all of.
Pet scans machine at the separate line that adult a scanner and a microscope.
Hello next question comes from General figure with William Blake.
Good morning. This is John Kaufman, Nonprint Krieger, I'd like to put them into a little bit on livestock here.
It'd be great to get a sense of your expectation pull up the outlet looks like not just in the coming quarter too, but really into 2021 and over the medium term. So I guess a couple questions within that first how much of residual impact will the processing capacity issues half and then second on the lower food.
Service demand.
Let's just say hypothetically in the U S consumer really isn't ready to go out to restaurants until.
Bring her summer of 2021.
Do you expect producers to exit and then your survey smaller and market or is it more <unk>.
Produces realized with us.
Period of limited profitability, but.
And just turned sideways and.
They stay in the market. Thank you.
Sure. Thanks, John a few things on that I think the cubic trends that you're seeing in U S livestock and I say, yes to look at life X, 60% of our livestock business is actually outside the U S. Any grew at 4%.
So again this is going to speak to the diversity of our portfolio, but if you look at the sort of global trends, you're talking about with regards to the movement.
Eating out to eating and we do expect that to continue and the guidance feet given for the rest of the year is at that largely doesn't change dramatically. It's obviously too early to talent 2020 wine how that ultimately adjust the second factor to consider.
Lifestyle overall is the packing plants, which I've been an issue in the U S packing plant capacity in the U S still looks to be about 95% to 97% and and some businesses that may be good but that does continue to backup animals.
But again this is mostly U S trying although we have seen.
You isolated issues outside of the U S and year up Australia, and some other markets.
But again I think what produces are doing are doing their best to actually.
Alter where they can.
The flow of animals. This is much easier for poultry to do given they only have to make decisions on a 45 day pigs can do it over six months, though I think you will see a slight reduction.
And the U S <unk>.
And park it is much harder for cattle producers muscles animals are already here. So we do see cattle probably continuing.
Two struggled probably see the first half.
Of next year, but I think the third factor beside the dining die now and packing plants to consider is actually the export market. What is really help maintain a lot of the U S. Livestock flows has been the export market with the largest player there clearly being China and given ASF, they're still need a a tremendous amount of park so at.
Those are the three factors that were considering that gives us confidence that to your question in the short <unk> medium term in general livestock has grown around 5%, obviously, it's been a little lower than the last few years and I think you could get international. It's four we were negative in the U S. We do thank and the medium term it goes back to normal levels, but we do thank.
Laptop will continue to be challenged certainly that here and likely at least at the first half of next year. Thanks John.
Our next question comes from Michael Aitken with Bank of America.
Hi, Thanks for taking the question.
To sort of a quick ones from me first on the guide.
For revenues guidance.
Six four girls I, just Wanna make sure my Mr 19th.
This 4% of the second quarter over five nine year to dates or end of the range Maxine claws.
Pretty meaningful deceleration from the second quarter on most trends.
So I'm just wondering if you could go into the bathroom.
We're going to the 3%, 1.6% when you're done with this quarter you talk about second William in the fall and winter.
Assumptions now.
Number one.
Going on there and then.
And then the second question again on the.
<unk>.
Knowledge instrument you talked about.
A little bit follow ups is it an instrument only product will there be consumables attached to it.
Are you planning and different rollout in the U S versus international Thanks.
So just in terms of of your first question in terms of the guidance and revenue of the 3% to 6% growth. So to your point in the first half we grew 5%.
With a limited impact from Culver 19 in Q1 that would imply second half of 2% to 7% growth essentially I think it's first important to understand and the first half that 5% growth did have a contribution from acquisitions of about 1%, which we won't have that same contribution and the second half of the year because of the women.
Any of those acquisitions occurred last year, so that really brings you to organic growth of about 4% and the first half of the year, which is the real comparator for that implied to to 7% growth in the second half of the year, So really pretty balanced three first half and second half organically with the first quarter not really having a significant impact from cobin 19.
<unk> two question about what brings you to the low end of the range that would be a more severe impact of Covid 19, then we're seeing today across our markets. What takes you to a higher end of that range is thing soda stabilizing as they are for the rest of the year without a more rapid or more significant impact of cold and 19, Sharon and to take the.
Second half your question Mike on images.
We will be launching the U S N a Q at market that side of the U S. As we move into the end up to three Q for.
And there are consumables with the consumable consumables, obviously, we agents there, but there's also a reed so obviously with every Texas Don D V. That's done on the clouded <unk>. So there are both.
He used to prepare the specimen, but there's also more more importantly, the read out of on each test in the cloud. So if a consumable I suppose but it's almost like a different way of looking at it which is a cost per reed I hope that answers I think Mike.
My next question comes from.
Scott with J P. Morgan. Please go ahead.
Okay.
Oh, Chris all thank you for taking our questions and the first one is an African <unk> catch the Congress and you're prepared remarks talk about that we are in terms of <unk>.
Recovering China, how much of a heard has been rebuilt and would you expect this represented tailwind and the second half of the year.
And then another one of livestock. It seems a part of the dynamics of cool that is creating as producers switching to lower cost alternatives to what extent of this happening and how sticky do you think misnamed because if you think about recovery in 2021 and beyond thank you.
Sure. So we'll start with your question with regard to African flying fever in China.
What we've been seeing in China overall is that the larger more sophisticated integrated producers are starting to rebuild our heard.
As you saw very strong growth in our China business at 24%, what you're seeing underlying that is the beginning of the rebuild of these heard this is more isolated to sophisticated producers who can ensure biosecurity because to be clear. There is still African swine fever present in China. So I think what you're seeing is at some of the smaller backyard.
R.
Producers are not rebuilding there, but we are seeing some of the more sophisticated one is doing so.
And that is a positive trend for us because they would be more likely to use our product overall, but if you look at African flying fever, we are still predicting that China will have to continue.
Important pork insignificant amount offer the next few years, so that rebuild a slow because as I said, there, it's still asking swine fever in China in a few isolated markets as well.
Side of China. So I suppose if you look at that for China. It will continue to be at tailwind for us continuing to drive that China business as that card rebuild.
And with regard to your second question on livestock, and whether whereas some people are switching to lower cost alternative historically that has been the case. So people world trade down what slightly different is this is a pandemic with a recession and I say that because as long as there is more protein and people need the <unk>.
Nice goes down so hamburger meat right now is actually still pretty cheap. So historically, we would see in a recession people tray down from beef pork.
A chicken to AG. So we think that's still a longer term trend, but with the disruption right now any overcapacity you were still seeing some other protein style and certain market on a relative basis not be that expensive.
So I think.
I would say your overall hypothesis, all with a medium to long term is true although in certain market given overcapacity. The difference in price is not as dramatic as it normally.
Hello welcome.
Mm Hmm Louise Formula cancel it. Please go ahead.
Hi, Thanks for taking my question. So I wanted to ask you how close at 19 has changed the way you do business on both the livestock and companion animals side, what efficiencies have emerged and what can be here. This day. Thank you.
Sure. Thanks, Louise I think similar to all businesses. We are we'd have to adjust the way we operate and I've been incredibly impressed at the resilience of our colleagues and our customers and their creativity. So the first trying to <unk>, obviously moved a lot more to doing virtual of seminars are webinars.
Two handling orders and things like that by following our customers have adopted two more telemedicine in certain markets around the world and if you look at more broadly in the U F in in certain Marcus outside the U S. T E commerce.
So that is obviously for us it's supporting our producers are veterinarian pet owners to make sure. They can access our products wherever they need but I think some of the skills that our field forces now learning.
One is that will help us in the future.
Obviously reduced some of the travel that some of them had to do but our <unk>.
Cross the world.
Businesses are allowing are actually vaccine customers now it's not as many customers as they saw before in a day and that has to be both a customer in a colleague feeling comfortable in a given market, but it's also have to flex obviously, given some of the playoffs in the U S at geographically and across the world.
A lot more flexibility there. So I think it's both our customers getting creative and flexible and our feel fourth and kind of our capability to over all the company to be able to meet our customers where they are so I think I'm quite impressed at how our colleagues and our customers have adapted.
My next question comes from David Westenburg claim Guggenheim. Please go ahead.
Alright, thanks for taking the questions and congrats on a great corner. So for my first question are you anticipating any kind of competitive lunch and then Durham Court in Durham in the next year say 2021, I know, we've heard about potential competitive launches for.
Probably five years now, but just trying to kind of feels a little bit different and then for my second question is on the diagnostic platform is there any limitation to the sample type stay blood fecal year and.
You can maybe physical tissue aside drops and is there a component that might have every agent to it. Thank you.
Sure. So I'll start David with your first question on the germ portfolio. We were obviously quite pleased with his performance in the corner growing 24%.
This is now obviously, a blockbuster products as well as category in to your point, we have expected competition for a while.
Given the attractiveness of the factor at this point in time, we have very little intelligence is you know in our in our industry with regards to competitive launches back based on what we know today, we are not expecting a competitive launch in the rest of 2020 and likely the first half of 2021, obviously, that's only subject to change since that we don't know exactly what our competitors they're doing by we continue.
Believe that we will have competition in the space that we at that point do not believe within the next six to 12 months.
So our focus right now in our dorm portfolio is building those brands as big as we can and as you saw on the quarter our focus on direct to consumer advertising in the U S to continue to grow our sure and to build the market itself.
So your second question with regards to that platform the images platform.
But we're saying is it's the first fecal will be the first.
Obviously, it could look at lots of others, that's still product that it's still in a research and development to look at other types such as honestly blood.
And other <unk> those are not think we are prepared at this point to discuss but obviously the platform lends itself to be able to do multiple different tissue types.
Thanks, so much.
Our next question comes from belonging Bob from Berkeley.
And money on Thanksgiving My question.
So coupons costly consumerism material changing the come to the landscape with a new number two company. So I would like to understand your thoughts on Monday, and I am calling band module means probably industry unplug.
The number one pumping.
Secondly, elite championing technology ultimate so I want to explode or when I'll be priority ideas mentioned beach stolen data analytics and one.
And an actual tones.
<unk> drive Williams notation looking to measure our mutual both thank you.
Sure. Thanks, a lot of a for starters on the combination of a langkow and there.
As I said previously we don't really see this is changing the competitive landscaping any dramatic way. We've competed against both of them many times before obviously.
Acquisition of thereby Elench, all will increase their business in the OTC space, where we honestly don't really operate we do in the direct to consumer outside but not any over the counter so it's not a space, it's important to us, especially with our focus on the veterinarian relax more of a retail.
Market there so we don't foresee that changing it they're both been well capitalized competitors. Historically, so we don't see that as a major change with regards to digital and data analytics I think it's an added to both.
Both a revenue driver as we announced today with images certainly looking at products that drive revenue such as platform such as that we are also spoken about precision livestock farming. So the the numbers of ways in both companion animals livestock that this continues to help us drive revenue in.
But it's also an area, where we can also be much more efficient.
Better targeting our customers.
Looking at new ways to E commerce, and other channels, we've donaldson quite exciting things.
And China for example, lighting, our own Revolution cases, there and leveraging different tools and digital data to just also make us more efficient so to drive revenue and just increase our efficiency. My next question tongue Nathan linked with Goldman Sachs. Please go ahead.
I wanted to start with some parakeets trio.
Mention the clinic penetration is occurring I think it a more moderate teeth and what you initially anticipated.
Because you know just be great today your view on kind of what you seem to a bar, maybe what what factors of how the biggest.
Impact on piece about two and do you think the will see the typical seasonality that you usually see in the parents didn't Bud business, obviously, a lot different about it.
Of this year, then maybe path here, if I could just opted upfront on the vet channel overall how much.
So the strength do you think.
Versus what might be excuse me more sustainable as we think about.
Trying to not part of your business over the balance of the year.
Thank Nathan so as we look at it.
Again, I'm, sorry, it's giving a distribution in late March in like the products and April right in probably the height of.
<unk> at least in the U S.
And what we seem to date is that that was more difficult for clinics to take on new products that often something that required in person meeting training us that et cetera. So we saw it slate.
No fewer penetration of clinics, but what we've been incredibly pleased about why we've given the guidance of $100 million to $125 million is that.
Corporate accounts ones that we engaged quite early outlet larger clinic and the one in those clinic has grown faster than we.
Expected. So I think that's been a positive so again for continuing to grow our penetration up clinics, but we're quite pleased with the sure and what we're also pleased about it.
It had less of an impact.
Certainly in cannibalizing some parents. So we certainly taken chair from others by our data also suggest for also bringing new people back to the category of oral parasiticide, which we think is it pretty exciting there so.
I think.
Whether it if it'll be a typical season.
With regards to.
Q2 year over year, there is still down I think about 3%, but if it's significant improvement.
Thank you thought in the U S at the beginning of the quarter, but what's really interesting and what what might affect your second your questionnaire is that the spending per visit.
So latest data Wilson.
Maybe up about 7%.
We do think that's going to moderate over time. This is probably people buying more.
Of the products that they don't have to return to the vet in case, there's some things so we do expect that.
Moderate.
In the coming quarters, but that might mean that people may versus the normal historical six months fixed.
Okay first satisfied maybe they bought more so we will see that that goes but we are expecting that too moderate.
So I think overall, we're looking for continued positive.
That is traveling companion animals, but I think it will be dependent geography by geography.
She comes from Kathy minor you with talent and company. Please go ahead.
Thank you. Good morning, two questions first is going back to the German.
Talked about the trends were good and people are staying home with the pets more could we anticipate greater near term sales for both Africa.
Both the U S N O U S.
Second question just on companion.
About the vet visits in the greater revenue per visit have you seen.
This is still working its way through the system or do you think we're already there and just to clarification on the share repurchased I just wanted to clarify that is in fact still on hold thank you.
Yeah, So I'll take the questions on dermatology on the entree repurchase so in terms of the darn portfolio. If you look back to last year, we had over $750 million themselves and we grew 29% right obviously with a bigger base of revenue we were expecting that growth rate to slow down when you look.
Year to date, however, we've grown 25% and that has exceeded our expectations and there's been a number of drivers and that we've continued to invest behind the portfolio to drive growth and we've seen a very positive return on that so we do expect to see better than expected performance in the darn portfolio than we would have when we started out the year.
Which is really pretty impressive considering the impact of Kobe 19, as well and it's a franchise that we will continue to make sure that we invest behind the growth.
In terms of share repurchase we did mentioned on the last call that we were spending I'll share repurchase 422.
Also spending four Q3, and we will continue to evaluate that throughout the year.
My next question comes from Greg Gilbert with tourists.
Please go ahead.
Thanks.
Chris amount of question I'm, sorry, if this came up I don't think it's a bit about insurance both the companies involvement and then a broader industry question. So first question is what have you learned about pet insurance and what well on what did not go so well near launching that space and.
Separate from so S as involvement in that space longer term dishy broader based interesting pet owners buying insurance. It seems like everyone with pets sort of gripes about turn out of pocket yet utilization of insurance is quite low do you think that's an employer immediate employer mediated phenomenon.
That needs to be jumpstarted or or what are your thoughts on increasing.
Penetration of of insurance from the pet space over time. Thanks.
Sure. Thanks, Craig.
So when we enter this space it was really about assisting the pet owner and getting the Karen increasing access to care and supporting the vet and providing the best carry they can and often times of one of the challenges. There is a sort of unexpected expense. So our focus really has been and that's to get a product that's more attractive to the consumers to your <unk>.
The U S versus the rest of the world is underpenetrated and pet insurance, but we think the primary reason there is not because of employers or anything other than we think some of the product has not been as attractive to pattern. So we really felt that the way we launched this to focus on the pattern or would be attractive. We are pleased with our performance to date of.
Our product with regards to pumpkin, which is our pet insurance.
And we look at that what's going to drive that and what feedback.
We did get some feedback from veterinarian sedan concerns with regards to the inclusion of parasiticide. So we did change the.
That program, a little bit to look to focus more on diagnostics and this is part of continuing to like a new product and really iterate with our customers bolted pet owner than that to make it as attractive as we can this is still a very very small business relative to the rest of our business to be perfectly honest with you. It's not terribly material, but we are very pleased with how the company has been doing.
To date and most specifically in the number of new policy. They continued to attract in our goal is that we can make insurance.
Grow they'll overall market, which is not hard to do in the U S. I think it's only 2% to 3% versus other markets outside the U S.
Hello.
My next question is amazing Jacob.
Please go ahead.
Hi, this is broken up on behalf of months Jacob.
My first question was on your Dean antibodies.
How do you see these products being differentiated versus some of their comforters such as.
<unk> gone the brunt and how are you thinking about the market a bunch of Indiana.
Second question is.
Did increasing.
<unk> Harbor material embarked on your margins this quarter.
No longer than with continues increase in all the new channels, how should we think about the impact on on your on your margin Brooklyn. Thank you.
Sure I'll start with.
Michael antibiotics and I'll add.
Glad to take the second question with regard city alternative channels.
I don't think we don't have an approved product I was hard to say exactly how it would stack up but the focus on monoclonal antibodies, it's really a focus on a product with strong efficacy with a strong safety profile.
And these are large market for thanks for example, and the canine space.
We think that's our gotten really comfortable with monopole antibodies as is evidenced by our performance on side of point it really awesome.
You remember to get the product here dog every day, but I would say if you think about.
Antibodies, there really aren't any product.
Thursday, and the cat space.
A final antibiotics.
Really very little existing products that cat owners or.
Can you. So we're quite excited but until we have a profile it'd be hard to stay very specifically like certainly from our clients and safety perspective, and accuracy. We think it'll be very strong products that we think that and pet owners will be quite excited about so Glen do you want to take a second pregnant sure. So in terms of the impact of alternative Trump channels on our margins. It did not have a material.
And that's just based on the overall size of ourselves in those channels right. It really is limited Georgia.
While the channel has expanded significantly in the quarter.
Percent of ourselves so it's still not a big impact.
On the on the overall margin, but just to get a sense of the growth that we have seen in 2019 and are you a companion that'll business. The alternative channels represented about 100 million.
A sales for the year and this quarter alone in cue to that number was about $50 million. So that gives you a sense of the rapid increase we're seeing in these channels, but it's still till small over an overall portion of our business to really impact overall.
Hello margins.
And there does appear to be no further questions at this point, how can I will call back over to your secret menu this color lines.
Okay, well, thanks, everybody I want to thank you for your questions and for your continued interested as the lettuce.
While they're still many uncertainties around the impact and a resolution to cope at 19, the fundamental strength of our business and industry. We believe are proven and unchanged and we remain very confident what's the what else can achieve this year based on the diversity of our portfolio to resiliency of our business and certainly the spirit of our colleagues. So thanks for joining us today.
And we disconnect anytime.
[music].
Three.
[noise].